Creo Medical (GB:CREO) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Creo Medical Group PLC reports stable operating costs and a 78% increase in core technology sales to £1.6m for the first half of 2024, driven by the adoption of their Speedboat UltraSlim device and expansion in training centers. Despite a slight dip in total revenue to £15.2m and a larger EBITDA loss of £10.5m, the company has announced a strategic partnership with Micro-Tech and a conditional placing to mitigate sales completion risks. Creo’s innovative medical devices continue to make headway in robotic surgery and endoscopic procedures, promising growth and expansion in the upcoming months.
For further insights into GB:CREO stock, check out TipRanks’ Stock Analysis page.
